{
  "id": "mhgap#risk_safety_9d9471ed",
  "content": "on methylphenidate treatment. monitoring for improvement in symptoms and\ny There is limited evidence on efficacy and tolerability prevention of adverse effects.\nbeyond 12 weeks and on treatment satisfaction. y A specialist care provider trained on management\ny There are increasing concerns related to of ADHD should reassess the child/adolescent’s\novermedicalization and overtreatment of ADHD management plan for ADHD at least once per year.\nin children. y The rationale for specialist assessment before\nprescription of methylphenidate is that\ndiagnosis of ADHD requires specialist clinical\njudgement especially given the risks of misuse\nof methylphenidate.\n28\n3. Recommendations\nResearch gaps Implementation considerations\ny There is a need for strengthened intervention y It is important to consider the health system’s\ndesigns that include long-term follow-up to capacity to enforce and implement protocols\nascertain lasting intervention effects, including for ADHD diagnosis; to prescribe and initiate\nadverse effects and acceptability in children and methylphenidate treatment by or in close\nadolescents. It is critically important that more consultation with a specialist; and to ensure\nevidence is made available on protocol adherence, careful clinical monitoring for side-effects, clinical\nmisuse/safety and treatment satisfaction when response, adherence, treatment acceptability, and\ntreatment with methylphenidate is prescribed and dose adjustment.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety on methylphenidate treatment. monitoring for improvement in symptoms and\ny There is limited evidence on efficacy and tolerability prevention of adverse effects.\nbeyond 12 weeks and on treatment satisfaction. y A specialist care provider trained on management\ny There are increasing concerns related to of ADHD should reassess the child/adolescent’s\novermedicalization and overtreatment of ADHD management plan for ADHD at least once per year.\nin children. y The rationale for specialist assessment before\nprescription of methylphenidate is that\ndiagnosis of ADHD requires specialist clinical\njudgement especially given the risks of misuse\nof methylphenidate.\n28\n3. Recommendations\nResearch gaps Implementation considerations\ny There is a need for strengthened intervention y It is important to consider the health system’s\ndesigns that include long-term follow-up to capacity to enforce and implement protocols\nascertain lasting intervention effects, including for ADHD diagnosis; to prescribe and initiate\nadverse effects and acceptability in children and methylphenidate treatment by or in close\nadolescents. It is critically important that more consultation with a specialist; and to ensure\nevidence is made available on protocol adherence, careful clinical monitoring for side-effects, clinical\nmisuse/safety and treatment satisfaction when response, adherence, treatment acceptability, and\ntreatment with methylphenidate is prescribed and dose adjustment. On methylphenidate treatment. monitoring for improvement in symptoms and\ny there is limited evidence on efficacy and tolerability prevention of adverse effects."
}